Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two hundred and fifty patients with acute myeloid leukaemia (AML) were randomized between 2 regimens of chemotherapy: TRAP and BARTS III. Overall, patients randomized to TRAP, which was the more intensive of the 2 regimens, fared slightly better (P = 0.06) than those on BARTS III. However, the improvement in survival associated with more intensive chemotherapy was substantial only for patients who had favourable prognostic features at presentation, such as a normal total leucocyte count, or absence of palpable liver, or, especially, age under 40. Indeed, for patients under 40, those allocated to the more intensive regimen (TRAP) lived considerably longer than those allocated to BARTS III (P less than 0.002) while for patients over 40 there was no material difference in survival between patients on the 2 protocols. It thus appears that intensive chemotherapy is likely to be more effective when favourable prognostic features are recorded.

Original publication

DOI

10.1038/bjc.1979.9

Type

Journal article

Journal

Br J Cancer

Publication Date

01/1979

Volume

39

Pages

69 - 86

Keywords

Adolescent, Adult, Aged, Antineoplastic Agents, Child, Child, Preschool, Clinical Trials as Topic, Cyclophosphamide, Cytarabine, Daunorubicin, Drug Administration Schedule, Drug Therapy, Combination, Humans, Leukemia, Myeloid, Acute, Mercaptopurine, Methotrexate, Middle Aged, Prednisolone, Random Allocation, Thioguanine, Vincristine